First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the second-line treatment after the failure of immunotherapy-based first-line remains elusive. Taking into account the w...

Full description

Bibliographic Details
Main Authors: Giuseppe Cabibbo, Maria Reig, Ciro Celsa, Ferran Torres, Salvatore Battaglia, Marco Enea, Giacomo Emanuele Maria Rizzo, Salvatore Petta, Vincenza Calvaruso, Vito Di Marco, Antonio Craxì, Amit G. Singal, Jordi Bruix, Calogero Cammà
Format: Article
Language:English
Published: Karger Publishers 2021-11-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
sequential treatment
immunotherapy
Online Access:https://www.karger.com/Article/FullText/520278

Internet

https://www.karger.com/Article/FullText/520278

Similar Items